

In re Application of: Britta HARDY et al.
Serial No.: 10/577,679
Filed: April 28, 2006
Office Action Mailing Date: January 22, 2008

Examiner: NIEBAUER, Ronald T.
Group Art Unit: 1654
Attorney Docket: 31831

In the Claims:

1-35. (Canceled)

36. (Currently Amended) An isolated peptide comprising ~~an~~ the amino acid sequence ~~consisting of set forth in~~ SEQ ID NO:6 or 10, the peptide being no more than 50 amino acids in length.

37. (Currently Amended) An isolated peptide consisting of ~~an~~ the amino acid sequence as set forth ~~by~~ in SEQ ID NO:6 or 10.

38. (Previously Presented) The isolated peptide of claim 36, wherein the peptide is a cyclic peptide.

39-43. (Canceled)

44. (Currently Amended) A composition-of-matter comprising a peptide which consists of the amino acid sequence set forth in SEQ ID NO: 6 and an additional peptide which consists of the amino acid sequence set forth in SEQ ID NO: 10. at least two peptides, each independently consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 6, 8, 10 and 12.

45. (Canceled)

46. (Currently Amended) A pharmaceutical composition comprising as an active ingredient ~~a~~ the peptide ~~comprising an amino acid sequence consisting of SEQ ID NO:2, 6, 10 or 12, said peptide being no more than 50 amino acid residues in length of claim 36~~ and a pharmaceutically acceptable carrier or diluent.

In re Application of: Britta HARDY et al.
Serial No.: 10/577,679
Filed: April 28, 2006
Office Action Mailing Date: January 22, 2008

Examiner: NIEBAUER, Ronald T.
Group Art Unit: 1654
Attorney Docket: 31831

47-52. (Canceled)

53. (Currently amended) A composition for targeting a drug to endothelial cells, the composition comprising the drug fused to ~~the isolated peptide of claim 37~~ a peptide consisting of the amino acid sequence set forth in SEQ ID NO:6 or 10.

54-57. (Canceled)

58. (Currently amended) The pharmaceutical composition of claim 46, wherein the ~~isolated~~ peptide is a linear peptide.

59-61. (Canceled)

62. (Previously Presented) The pharmaceutical composition of claim 46, wherein the peptide is a cyclic peptide.

63-70. (Canceled)

71. (New) The isolated peptide of claim 36, wherein the peptide is a linear peptide.

72. (New) A composition for targeting a drug to endothelial cells, the composition comprising the drug fused to the peptide of claim 36.

73. (New) A pharmaceutical composition comprising as an active ingredient the peptide of claim 37, and a pharmaceutically acceptable carrier or diluent.

In re Application of: Britta HARDY et al.
Serial No.: 10/577,679
Filed: April 28, 2006
Office Action Mailing Date: January 22, 2008

Examiner: NIEBAUER, Ronald T.
Group Art Unit: 1654
Attorney Docket: 31831

74. (New) A composition-of-matter comprising a peptide which comprises the amino acid sequence set forth in SEQ ID NO:6, wherein said peptide is no more than 50 amino acids in length, and an additional peptide which comprises the amino acid sequence set forth in SEQ ID NO:10, wherein said additional peptide is no more than 50 amino acids in length.